Propane

Propane

SCHEMBL4054745

CCC.CNC.N

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propane SCHEMBL9248047 1.00
Propane SCHEMBL23590 0.94
Propane SCHEMBL25366971 0.94
Propane SCHEMBL10466038 0.88
Propane SCHEMBL28102546 0.88
Propane SCHEMBL28551707 0.88
Propane SCHEMBL28102545 0.88 KDM4E (0.40)
Propane SCHEMBL28015864 0.82
Dimethylamine SCHEMBL292029 0.79
Propane SCHEMBL187937 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1748786-A4 DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS VICURON PHARM INC (US) 2009-07-15 EP disclosed
EP-1748786-A2 DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS Vicuron Pharmaceuticals, Inc. (US) 2007-02-07 EP disclosed
WO-2006078277-A2 DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS VICURON PHARMACEUTICALS INC. (US) 2006-07-27 WO disclosed
EP-1565201-A1 METHODS OF ADMINISTERING DALBAVANCIN FOR TREATMENT OF BACTERIAL INFECTIONS Vicuron Pharmaceuticals, Inc. (US) 2005-08-24 EP disclosed
WO-2004045636-A1 METHODS OF ADMINISTERING DALBAVANCIN FOR TREATMENT OF BACTERIAL INFECTIONS VICURON PHARMACEUTICALS INC. (US) 2004-06-03 WO disclosed
WO-2004045637-A1 DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS VICURON PHARMACEUTICALS INC. (US) 2004-06-03 WO disclosed
WO-2004046196-A2 COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS WITH PROTEIN-DALBAVANCIN COMPLEXES VICURON PHARMACEUTICALS INC. (US) 2004-06-03 WO disclosed